NCT04966494

Brief Summary

Hypertriglyceridemia is a serious condition in the Mexican population and it is considered a major risk factor for cardiovascular disease. Current efforts to prevent dyslipidemia and lipids alteration include the development of functional products as an alternative for the management of hypertriglyceridemia. Common beans (Phaseolus vulgaris L.) are a recognized good source of bioactive compounds, mainly phenolic compounds, total dietary fiber (insoluble and soluble fiber, resistant starch and oligosaccharides), saponins, and phytosterols that exert hypolipidemic effects. In this sense, the development of beans-based food products is an alternative for improving the general health status. In previous work, a beans-oats snack bar formulation was found to be a promising potential functional product. In order to validate those results, the aim of this works was to assess a clinical trial was conducted with Mexican women to assess the effect of daily consumption of the functional product on serum triglycerides and certain plasma proteins involved in lipids metabolism in a clinical trial. The clinical trial was 2 months, randomized parallel study where 32 women with elevated triglycerides were randomized into the treatment group and control group. The Control group received nutritional orientation whereas the treatment group received the orientation and consumed 50 g of the product per day. Fasting blood samples were collected at baseline and the end of the study, obtaining serum and plasma for analysis of lipids profile, glucose, and biomarkers. To determine changes in plasma proteins, a 182 protein Human Obesity Antibody Array was used, and the results were analyzed using a bioinformatic-based analysis from Ingenuity Pathways Analysis (QIAGEN)

Trial Health

100
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
100

participants targeted

Target at P50-P75 for not_applicable

Timeline
Completed

Started Oct 2013

Typical duration for not_applicable

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

October 5, 2013

Completed
1.8 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

July 13, 2015

Completed
4 months until next milestone

Study Completion

Last participant's last visit for all outcomes

November 2, 2015

Completed
5.7 years until next milestone

First Submitted

Initial submission to the registry

July 2, 2021

Completed
17 days until next milestone

First Posted

Study publicly available on registry

July 19, 2021

Completed
Last Updated

July 19, 2021

Status Verified

July 1, 2021

Enrollment Period

1.8 years

First QC Date

July 2, 2021

Last Update Submit

July 14, 2021

Conditions

Keywords

Common beansOatsProteomic AnalysisPhenolic compoundsDietary Fiber

Outcome Measures

Primary Outcomes (2)

  • Triglycerides

    Significant change

    8 weeks

  • Glucose

    Significant change

    8 weeks

Study Arms (2)

BOSB Group

EXPERIMENTAL

This group consumed a common beans and oats snack bar (BOSB) for 8 weeks.

Dietary Supplement: BOSB

Control Group

NO INTERVENTION

This group corresponded to hypertriglyceridemic women who does not consume BOSB

Interventions

BOSBDIETARY_SUPPLEMENT

BOSB consisted on a oats (26 %), common beans (30 %), water and emulsifier-based snack bar, administered daily (50 g/day) during 8 weeks.

BOSB Group

Eligibility Criteria

Age18 Years - 45 Years
Sexfemale
Healthy VolunteersYes
Age GroupsAdult (18-64)

You may qualify if:

  • No current diagnoses of illnesses.
  • Triglycerides levels among 150 and 350 mg/dL.
  • No allergies to common beans and oats.
  • Not pregnant or lactating.

You may not qualify if:

  • If they had current diagnoses of diabetes, hypertension, irritable bowel syndrome, or cancer.
  • Taking anti-inflammatory drugs.
  • Fasting glucose \>100 mg/dL, total cholesterol \>240 mg/dL, LDL C\>160 mg/dL.
  • Reported intolerances to BOSB ingredients.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Related Publications (1)

  • Ramirez-Jimenez AK, Luzardo-Ocampo I, Cuellar-Nunez ML, Anaya-Loyola MA, Leon-Galvan MF, Loarca-Pina G. Daily Intake of a Phaseolus vulgaris L. Snack Bar Attenuates Hypertriglyceridemia and Improves Lipid Metabolism-Associated Plasma Proteins in Mexican Women: A Randomized Clinical Trial. Front Nutr. 2022 Jun 3;9:890136. doi: 10.3389/fnut.2022.890136. eCollection 2022.

MeSH Terms

Conditions

HypertriglyceridemiaObesity

Condition Hierarchy (Ancestors)

HyperlipidemiasDyslipidemiasLipid Metabolism DisordersMetabolic DiseasesNutritional and Metabolic DiseasesOverweightOvernutritionNutrition DisordersBody WeightSigns and SymptomsPathological Conditions, Signs and Symptoms

Study Officials

  • Guadalupe Loarca-Piña, Ph. D.

    Universidad Autonoma de Queretaro

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
DOUBLE
Who Masked
PARTICIPANT, INVESTIGATOR
Purpose
BASIC SCIENCE
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Associate Researcher

Study Record Dates

First Submitted

July 2, 2021

First Posted

July 19, 2021

Study Start

October 5, 2013

Primary Completion

July 13, 2015

Study Completion

November 2, 2015

Last Updated

July 19, 2021

Record last verified: 2021-07

Data Sharing

IPD Sharing
Will share

Data will be available upon reasonable request

Shared Documents
ICF, CSR
Time Frame
10 years